Skip to content

Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug

  • Chad Cipiti

Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead’s new hepatitis C virus (HCV) drug. As Gregg Alton, Gilead’s Executive Vice President of Corporate and Medical Affairs, spoke, activists brought him a liver on a silver platter while chanting “Pills Cost Pennies, Greed Costs Lives,” “Shame, Shame, Shame,” and “Pharma Greed Kills.”

Read more

2014 Pipeline Report

  • Chad Cipiti

July 20, 2014 HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development Written by Polly Clayden, Simon Collins, Colleen Daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn…

Read more

New Hepatitis Resolution Is Passed at World Health Assembly; Challenges World Health Organization and Member States to Act

  • Chad Cipiti

Today, four years after introducing its first viral hepatitis resolution, the World Health Assembly (WHA)—the decision-making body of the World Health Organization (WHO)—passed the Hepatitis Resolution, which commits the WHO and United Nations (UN) member states to urgent action to address the global hepatitis pandemic, including that of hepatitis C virus (HCV).

Read more

TAGline Spring 2014

  • Chad Cipiti

NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS Spring 2014 The April Fools' Issue: April 1. This is the day upon which we are reminded of what we are on the other three hundred and sixty-four. —Mark…

Read more

2013 TAG Update

  • Chad Cipiti

TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.

Read more

TAGline Fall 2013

  • Chad Cipiti

The Domestic Issue: We're at a stalemate. This issue of TAGline underscores TAG’s commitment to ending AIDS in the United States and realizing the goals of the National HIV/AIDS Strategy.

Read more
Back To Top